BSRBR publications, information and news
The BSRBRs have been publishing academic output for nearly fifteen years. Below is a chronological list of the published academic peer reviewed papers from the BSRBRs which are a vital contribution to the evidence base on clinical management and patient safety.
The Registers' systematic collection and analysis of large amounts of patient data traces the effects of biologics drugs in long term use. In addition, a large number of poster and oral presentations have also been given in the UK, Europe and internationally. The majority of these papers are from the RA Register as the AS register is still collecting enough data to analyse significantly .
Thousands of people - patients, health professionals, managers, administrators and pharmaceutical sponsors have all contributed to creating this output. BSR is proud to be part of that partnership.
Most of the papers are available for FREE via open access. A 'DOI' -Digital Object Identifier - has been included to help locate the paper, simply copy and paste'DOI' + its number as listed into the URL address bar and tap return. One of the top items will almost certainly link you directly to the paper you want.
Year of publication
2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004
2015
The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era.
Morgan C. et al Rheumatology (Oxford) May 13. pii: kev105. [Epub ahead of print]
Patients receiving anti-TNF therapies experience clinically important improvements in RA-related fatigue: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Druce K.L. et al Rheumatology (2015) 54 (6): 964-971 DOI:10.1093/rheumatology/keu390
Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Mercer L. et al Ann Rheum Dis, [Epub ahead of print], DOI:10.1136/annrheumdis-2013-204851 Print ver. 2015; 74:1087–1093 DOI:10.1136/annrheumdis-2013-204851
Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying ant-rheumatic drugs: long-term safety and survival using prospective observational data.
Morgan C.L. et al Rheumatology (Oxford), 53(1), 186-94 DOI: 10.1093/rheumatology/ket333
The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA.
Závada J. et al Ann Rheum Dis, 73(1), 252-255. DOI:10.1136/annrheumdis-2012-203102
2013
A threshold hazard model for estimating serious infection risk following anti-tumor necrosis factor therapy in rheumatoid arthritis patients.
Fu B. et al J Biopharm Stat, 23(2), 461-76 DOI:10.1080/10543406.2011.616973
Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
Galloway J. et al Ann Rheum Dis, 72(2), 229-234. DOI:10.1136/annrheumdis-2011-201108
Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register.
McErlane F. et al Rheumatology (Oxford), 52(10), 1905-1913. DOI:10.1093/rheumatology/ket248
Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population.
Mercer L. et al Rheumatology (Oxford), 52(1), 91-98. DOI:10.1093/rheumatology/kes350
Anti-TNF therapy in women with rheumatoid arthritis with a history of carcinoma in situ of the cervix.
Mercer L. et al Ann Rheum Dis, 72(1), 143-144. DOI:10.1136/annrheumdis-2012-201814
2012
The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register.
Mercer L. et al Annals of the rheumatic diseases, 71(6), 869-874. DOI:10.1136/annrheumdis-2011-200622
Effectiveness of Rituximab in Patients with Rheumatoid Arthritis: Observational Study from the British Society for Rheumatology Biologics Register.
Soliman M. et al J Rheumatol, 39(2), 240-246. DOI:10.3899/jrheum.110610
Rituximab or a second anti-TNF therapy for rheumatoid arthritis patients who have failed their first anti-TNF? Comparative analysis from the British Society for Rheumatology Biologics Register.
Soliman M. et al Arthritis Care Res (Hoboken), 64(8), 1108-1115 DOI:10.1002/acr.21663
2011
Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.
Davies R. et al Ann Rheum Dis, 70(10), 1831-4. DOI:10.1136/ard.2011.153536
The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Galloway JB et al Rheumatology, 50(7), 1341-1342. DOI:10.1093/rheumatology/ker146
Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly.
Galloway J. et al Rheumatology (Oxford), 50(1), 124-131. DOI:10.1093/rheumatology/keq242
Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.
Galloway J. et al Ann Rheum Dis, 70(10), 1810-1814. DOI:10.1136/ard.2011.152769
Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008.
Hyrich K. et al Rheumatology (Oxford), 50(1), 117-123. DOI:10.1093/rheumatology/keq209
Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Soliman M et al Annals of the rheumatic diseases, 70(4), 583-589. DOI:10.1136/ard.2010.139774
Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers.
Strangfeld A. et al Rheumatology (Oxford), 50(1), 146-151. DOI:10.1093/rheumatology/keq301
Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register.
Verstappen S. et al Annals of the rheumatic diseases, 70(5), 823-826. DOI:10.1136/ard.2010.140822
Genome-wide association study of genetic predictors of anti-tumour necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci.
Plant D. et al Arthritis Rheum, 63(3) 645-53 DOI 10.1002/art.30130
2010
Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register.
Dixon W. et al Annals of the Rheumatic Diseases, 69(6), 1086-1091. DOI:10.1136/ard.2009.120626
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).
Dixon W. et al Annals of the Rheumatic Diseases, 69(3), 522. DOI:10.1136/ard.2009.118935
Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for Rheumatology Biologics Register.
Dixon W. et al Arthritis Care Res (Hoboken), 62(6), 755-63. DOI:10.1002/acr.20129
Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis.
Harrison M. et al Health Qual Life Outcomes, 8(1), 21. DOI:10.1186/1477-7525-8-21
Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register.
Lord P. et al Rheumatology (Oxford), 49(3), 563-567. DOI:10.1093/rheumatology/kep422
No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register.
Lunt M. et al Arthritis and Rheumatism, 62(11), 3145-3153. DOI:10.1002/art.27660
Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register.
Saad A. et al Rheumatology (Oxford), 49(4), 697-705. DOI:10.1093/rheumatology/kep423
Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies.
Saad A. et al Arthritis Care Res (Hoboken), 62(3), 345-53. DOI:10.1002/acr.20104
Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register.
Verstappen S. et al Rheumatology, 49(8), 1570-1577. DOI:10.1093/rheumatology/keq131
2009
Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-TNF{alpha} therapy.
Harrison MJ et al Ann Rheum Dis, 68(2), 209-215. DOI:10.1136/ard.2007.087288
Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity.
Hyrich K. et al Rheumatology (Oxford), 48(10), 1323-7. DOI:10.1093/rheumatology/kep242
Different Methods of Balancing Covariates Leading to Different Effect Estimates in the Presence of Effect Modification.
Lunt M et al American Journal of Epidemiology, 169(7), 909-917. DOI:10.1093/aje/kwn391
Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register.
Saad A.A. et al Arthritis Res Ther, 11(2), R52. DOI:10.1186/ar2670
The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis.
Harrison M.J. et al Qual Life Res. 18(9) 1195-1205
2008
Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug.
Hyrich K.L. et al Rheumatology (Oxford), 47( 7), 1000-5.
The British Society for Rheumatology Biologics Register: 6 years on.
Hyrich K.L. et al Rheumatology (Oxford), 47(10) 1441-3 DOI 10.1093/rheumatology/ken242
2007
Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
Brennan A. et al Rheumatology (Oxford), 46( 8), 1345-54. DOI: 10.1093/rheumatology/kem115
Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies.
Dixon W.G. et al Arthritis Rheum, 56( 9), 2896-904. DOI: 10.1002/art.22808
Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.
Dixon W.G. et al Arthritis Rheum, 56( 9), 2905-12. DOI: 10.1002/art.22809
Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
Hyrich K.L. et al Arthritis Rheum, 56( 1), 13-20. DOI:10.1002/art.22331
2006
Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register.
Dixon W.G. et al Arthritis and Rheumatism, 54, 8, 2368-2376. DOI:10.1002/art.21978
Baseline Comorbidity Levels in Biologic and Standard DMARD Treated Patients with Rheumatoid Arthritis: Results from a National Patient Register.
Hyrich K.L. et al Annals of the Rheumatic Diseases, 65, 7, 895-898. doi:10.1136/ard.2005.043158
Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying anti-rheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register.
Hyrich K.L. et al Arthritis and Rheumatism, 54, 6, 1786-1794. DOI: 10.1002/art.21830
Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: Results from a national population register.
Hyrich K.L. et al Arthritis and Rheumatism, 54, 8, 2701-2702. DOI: 10.1002/art.22028
Predictors of response to anti-TNF-{alpha} therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich K.L. et al Rheumatology, 45, 12, 1558-1565. DOI:10.1093/rheumatology/kel149
UK Consultant Rheumatologists' access to biological agents and views on the BSR Biologics Register.
Kay L.J. et al Rheumatology (Oxford) 45(11) 1376-9 DOI:10.1093/rheumatology/kel333
2005
The British Society for Rheumatology biologics register.
Watson K. et al Ann Rheum Dis, 64 Suppl 4, iv42-3. DOI:10.1136/ard.2005.042499
2004
Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.
Hyrich K. et al Ann Rheum Dis, 63(12), 1538-43. DOI:10.1136/ard.2004.024737
2003
British Society for Rheumatology Biologics Register.
Silman A. et al Ann Rheum Dis, 62 Suppl 2, ii28-9. DOI:10.1136/ard.62.suppl_2.ii28
The role of the British Society for Rheumatology Biologics Register (BSRBR) and the NICE guidelines for anti-TNF therapy.
Watson K., Hyrich K. Musculoskeletal Care 2003 1(1) 58-64 DOI:10.1002/msc.39